UBS Upgrades Thermo Fisher Scientific (TMO) and Raises Price Target
On September 9, 2026, UBS upgraded its rating on Thermo Fisher Scientific from Neutral to Buy while raising the price target significantly—from $540 to $730. The move reflects a shift in sentiment toward life sciences tools companies that have seen their valuations fall despite continued revenue growth and margin expansion over recent years. The firm's upgrade is based not on Thermo Fisher’s most recent earnings but rather its projected performance for 2027, where UBS sees durable organic growth of at least 5% to 6%. The analysts also anticipate operating margin improvements and double-digit EPS growth driven by better biotech funding, reshoring investment, AI-driven R&D efficiency gains, market share expansion, and stabilization in China. UBS’s $730 target is notably higher than the current stock price and stands out compared to other Wall Street estimates. CLSA analyst Michael Luo had already set a slightly higher target of $748 earlier that week.
Tickers: $TMO
Topics: analyst upgrade life sciences tools price target increase Thermo Fisher Scientific